RYCAMED 75
RYCAMED 75
Active ingredient: Pregabalin 75 mg.
Dosage form: Hard capsule.
Packaging: Box of 3 blisters x 10 capsules.
Expiry date: 36 months.
Posology
The dose range is 150 to 600 mg per day given in either two or three divided doses.
Neuropathic pain
Pregabalin treatment can be started at a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.
Epilepsy
Pregabalin treatment can be started with a dose of 150 mg per day given as two or three divided doses.
Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. The maximum dose of 600 mg per day may be achieved after an additional week.
Generalised anxiety disorder
The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment should be reassessed regularly.
Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. Following an additional week the dose may be increased to 450 mg per day. The maximum dose of 600 mg per day may be achieved after an additional week.
Discontinuation of pregabalin
In accordance with current clinical practice, if pregabalin has to be discontinued, it is recommended this should be done gradually over a minimum of 1 week independent of the indication (see sections Special warnings and precautions for use and Adverse reactions).
Renal impairment
Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. As pregabalin clearance is directly proportional to creatinine clearance (see section Pharmacokinetic properties), dose reduction in patients with compromised renal function must be individualised according to creatinine clearance (ClCr), as indicated in Table 1 determined using the following formula:
Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the pregabalin daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4 hour haemodialysis treatment (see Table 1).
Table 1. Pregabalin Dose Adjustment Based on Renal Function
| Creatinine clearance (ClCr) (mL/min) | Total pregabalin daily dose* | Dose regimen | |
| Starting dose (mg/day) | Maximum dose (mg/day) | ||
| ≥ 60 | 150 | 600 | BID or TID |
| ≥ 30 – < 60 | 75 | 300 | BID or TID |
| ≥ 15 – < 30 | 25 – 50 | 150 | Once Daily or BID |
| < 15 | 25 | 75 | Once Daily |
| Supplementary dosage following haemodialysis (mg) | |||
| 25 | 100 | Single dose+ | |
TID = Three divided doses
BID = Two divided doses
* Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose.
+ Supplementary dose is a single additional dose.
Hepatic impairment
No dose adjustment is required for patients with hepatic impairment (see section Pharmacokinetic properties).
Paediatric population
The safety and efficacy of pregabalin in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. Currently available data are described in sections Adverse reactions, Pharmacodynamic properties and Pharmacokinetic properties but no recommendation on a posology can be made.
Elderly
Elderly patients may require a dose reduction of pregabalin due to a decreased renal function (see section Pharmacokinetic properties).
Administration
Pregabalin may be taken with or without food.
Pregabalin is for oral use only.
INDICATIONS
Neuropathic pain
Pregabalin is indicated for the treatment of peripheral and central neuropathic pain in adults.
Epilepsy
Pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalization.
Generalised anxiety disorder
Pregabalin is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
CONTRAINDICATIONS
Hypersensitivity to the pregabalin or to any of the excipients.
